|Bid||0.70 x 1100|
|Ask||2.49 x 900|
|Day's Range||1.6500 - 1.7100|
|52 Week Range||0.7600 - 7.6000|
|Beta (3Y Monthly)||1.48|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 13, 2019 - Mar 18, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||4.60|
OpGen, Inc. (OPGN) today announced that it has provided the final report for completion of the contract from the Centers for Disease Control and Prevention (CDC) to develop smartphone-based clinical decision support solutions for antimicrobial stewardship (AMS) and infection control in low- and middle-income countries. OpGen worked with partners ILÚM Health Solutions, LLC (“ILÚM”), a wholly owned subsidiary of Merck’s Healthcare Services and Solutions, and Universidad El Bosque (UEB) of Bogota, Colombia led by Maria Virginia Villegas, M.D., M.Sc.
OpGen, Inc. (OPGN) announced today it has received approval from the Instituto Nacional de Vigilancia de Medicamentos y Alimentos (INVIMA), Colombia’s regulatory authority for food, drugs, and medical devices, to market its rapid pathogen identification products in the country. Earlier this year OpGen established a subsidiary, OpGen Colombia, SAS, to commercialize the Company’s precision medicine products in Colombia and more broadly through South America.
NEW YORK, Nov. 21, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
OpGen, Inc. (OPGN) delivered earnings and revenue surprises of 3.64% and -1.43%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Conference call begins at 4:30 p.m. Eastern time today GAITHERSBURG, Md., Nov. 13, 2018 -- OpGen, Inc. (NASDAQ: OPGN) today reported financial and operating results for the.
The results of the study, which tested 670 remnant urine specimens from patients at increased risk for complicated urinary tract infections (cUTI), will be summarized and discussed in a peer-reviewed manuscript anticipated to be published in 2019. “We are pleased to have completed this important milestone with our renowned collaborators as we evaluate potential improvements in cUTI management. This study represents the first use of the Acuitas AMR Gene Panel u5.47 (RUO) in the hands of clinical laboratories – an important step forward for our technology,” said Terry Walker, Senior Vice President R&D, OpGen, Inc. “We are encouraged by the preliminary results of the study and we look forward to completing the analysis of the results from the use of our technology to evaluate these cUTI specimens.
NEW YORK, NY / ACCESSWIRE / August 2, 2018 / OpGen, Inc. (NASDAQ: OPGN ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 2, 2018 at 4:30 PM Eastern Time. To listen ...
Zacks.com featured highlights include: Hilton Grand, Fastenal, Catalyst Biosciences, OpGen and ConforMIS
Generally, investors love stocks with a low price-to-earnings (P/E) ratio. The idea is that the lower the P/E, the higher will be the value of the stock. The simple logic that a stock’s current market price does not validate (is not equivalent to) its higher earnings and therefore has room to run justifies investors’ inclination toward low P/E stocks.Source: ©iStock.com/CharlieAJA